GLP1R and Alzheimer disease: Furthermore, the GLP-1R agonist NLY01 improved AD symptoms by regulating the microglia-mediated conversion of reactive astrocytes and decreased memory deficits in 5xFAD and 3xTg-AD mice, indicating that NLY01 could be a viable therapy in AD [119].